NCNA NuCana plc ADRs

NuCana PLC is a clinical-stage biopharmaceutical company. It is focused on improving treatment outcomes for cancer patients by applying its ProTide technology. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$0.96  -0.02 (-1.55%)
As of 11/23/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  09/28/2017
Outstanding shares:  52,180,000
Average volume:  43,294
Market cap:   $49,831,900
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy